Tafinlar and Left ventricular dysfunction - a phase IV clinical study of FDA data

Summary:

Left ventricular dysfunction is reported as a side effect among people who take Tafinlar (dabrafenib mesylate), especially for people who are male, 60+ old, have been taking the drug for 6 - 12 months also take Mekinist, and have Metastatic malignant melanoma.

The phase IV clinical study analyzes which people have Left ventricular dysfunction when taking Tafinlar. It is created by eHealthMe based on reports of 16,296 people who have side effects when taking Tafinlar from the FDA, and is updated regularly.

What is Tafinlar?

Tafinlar has active ingredients of dabrafenib mesylate. eHealthMe is studying from 16,304 Tafinlar users. Check the latest studies of Tafinlar.

What is Left ventricular dysfunction?

Left ventricular dysfunction is found to be associated with 890 drugs and 792 conditions by eHealthMe. Check the latest studies of Left ventricular dysfunction.

On Jul, 20, 2026

16,296 people reported to have side effects when taking Tafinlar.
Among them, 28 people (0.17%) have Left ventricular dysfunction.

Could Tafinlar cause Left ventricular dysfunction?

Among these 28 people:

How long have people been on Tafinlar when they have Left ventricular dysfunction? *

What is the gender of people who have Left ventricular dysfunction when taking Tafinlar? *

female: 29.63 %
male: 70.37 %

What is the age of people who have Left ventricular dysfunction when taking Tafinlar? *

What are other drugs people take besides Tafinlar? *

What are other side effects people have besides Left ventricular dysfunction? *

Dyspnea (difficult or laboured breathing): 14 people, 50.00%
Ejection Fraction Decreased (systolic heart failure): 9 people, 32.14%
Oedema Peripheral (superficial swelling): 9 people, 32.14%
Pneumothorax (the presence of air or gas in the cavity between the lungs and the chest wall, causing collapse of the lung): 8 people, 28.57%
Device Dislocation: 8 people, 28.57%
Non-Hodgkin's Lymphoma (malignant (cancer) cells form in the lymph system): 7 people, 25.00%
Fever: 6 people, 21.43%
Abdominal Pain Upper: 5 people, 17.86%
Hyperglycemia (high blood sugar): 5 people, 17.86%
Infection: 5 people, 17.86%

What are the existing conditions these people have? *

Metastatic Malignant Melanoma (spreadable cancer tumour of melanine): 9 people, 32.14%
Lung Cancer - Non-Small Cell (lung cancer): 7 people, 25.00%
Non-Small Cell Lung Cancer Stage Iv: 5 people, 17.86%
Constipation: 2 people, 7.14%
Thyroid Cancer: 1 person, 3.57%
Malignant Melanoma Stage Iv (the cancer has spread to other places in the body, such as the lung, liver, brain, bone, soft tissue, or gastrointestinal (gi) tract. cancer may have spread to places in the skin far away from where it first started): 1 person, 3.57%
Malignant Melanoma (skin cancer rises from melancytes): 1 person, 3.57%
Lung Adenocarcinoma Stage Iv (the cancer has spread to other organs of the body, such as the other lung, brain, or liver): 1 person, 3.57%
Adverse Event: 1 person, 3.57%

* Approximation only. Some reports may have incomplete information.

Do you take Tafinlar and have Left ventricular dysfunction?

- Check whether Left ventricular dysfunction is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Tafinlar:

Tafinlar (16,304 reports)

Browse all side effects of Tafinlar:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Left ventricular dysfunction:

Left ventricular dysfunction (890 drugs)

Browse all the conditions that are associated with Left ventricular dysfunction:

Left ventricular dysfunction (792 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on dabrafenib mesylate (the active ingredients of Tafinlar) and Tafinlar (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.